//
The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
Heart Failure With Preserved Ejection Fraction in the Young
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems